Rezolute, Inc. cotiza a 4.87 USD y tiene una capitalización bursátil de $471M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase …
| Periodo | 2026-11 | 2026-09 | 2026-02 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.20 | $-0.22 | $-0.18 |
| Estimado | $-0.18 | $-0.14 | $-0.18 | $-0.26 |
| Sorpresa | — | -42.9% | -22.2% | +30.8% |
| Métrica | RZLT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -77.1% | -40.4% | -36.7% |
| ROA | -68.8% | -32.0% | -36.7% |
| Current Ratio | 9.68 | 2.84 | +6.84 |
| Debt / Equity | — | 0.28 | — |